According to The Fly, in a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Correvio Pharma Corp. (TSX: CORV). The company recieved Buy rating from H.C. Wainwright’s analyst Swayampakula Ramakanth.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.5% and a 34.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Tyme Technologies Inc.
Read also: Here’s Why AcelRx Pharmaceuticals (ACRX) Stock Skyrocketed Today
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Correvio Pharma Corp. with a C$8 average price target.
Based on Correvio Pharma Corp.’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of C$7.01 million. In comparison, last year the company had a GAAP net loss of C$8.3 million.
Correvio Pharma Corp. is a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
The company’s shares closed on Wednesday at C$4.84.
